Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
genetically attenuated Plasmodium falciparum Δmei2 sporozoites
- Development stage
- Phase 2
- Lead developer
- Leiden University Medical Center
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Genetically attenuated Plasmodium falciparum Δmei2 sporozoites is a live-attenuated whole-parasite vaccine candidate developed by the Leiden University Medical Center (LUMC) for the prevention of falciparum malaria. The vaccine utilizes a CRISPR-Cas9 engineered strain of *Plasmodium falciparum* where the *mei2* gene, which encodes an evolutionarily conserved RNA-binding protein, has been deleted. This genetic modification causes the parasite to arrest late in its liver-stage development, preventing the transition to the symptomatic blood-stage of infection. By allowing the parasite to persist longer in the liver than earlier-generation genetically attenuated parasites (GAPs), PfΔmei2 aims to elicit a broader and more potent repertoire of T-cell and antibody responses against pre-erythrocytic antigens, potentially providing enhanced protective immunity.
- Other names
- PfΔmei2 sporozoitesmei2-deleted P. falciparum sporozoitesmei-2-deleted P. falciparum sporozoitesmei 2-deleted P. falciparum sporozoitesgenetically attenuated parasite vaccine PfΔmei2
02
Targets
PfMei2 (Plasmodium falciparum Mei2-like protein)
Beyond the preview
Go deeper on genetically attenuated Plasmodium falciparum Δmei2 sporozoites.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on genetically attenuated Plasmodium falciparum Δmei2 sporozoites.